
    
      The duration of the study per participant will be up to approximately 6 years that will
      consist of a 14-day screening period (may be extended up to 8 weeks in pre-specified
      situations), a 49-week blinded treatment period (except for the subgroup of pediatric
      patients aged 3 to less than (<) 18 years enrolling directly in the open-label long-term
      follow-up phase), a 240-week open-label treatment period, and a 4-week post-treatment
      observation period.
    
  